Vivos Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Vivos Therapeutics, Inc. (VVOS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.40% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2023-03-30
- Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.90%, a 123.53% increase year-over-year.
- Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-03-31 was 0.85%, a 49.10% decline year-over-year.
- Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-03-31 was 1.67%.
- Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 3.40%, a 325.00% increase from fiscal 2021.
- Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 0.80%, a 100.00% increase from fiscal 2020.
- Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 0.40%, a 80.00% decline from fiscal 2019.
- Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2019 was 2.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | 3.40% 10-K · filed 2023-03-30 | ||||
| 2022-09-30 | 3.10% 10-Q · filed 2022-12-20 | ||||
| 2022-06-30 | 2.80% 10-Q · filed 2022-12-20 | ||||
| 2022-03-31 | 1.90% 10-Q/A · filed 2022-11-25 | ||||
| 2021-12-31 | 0.80% 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | 0.80% 10-Q · filed 2022-12-20 | ||||
| 2021-06-30 | 0.85% 10-Q · filed 2021-08-12 | ||||
| 2021-03-31 | 0.85% 10-Q · filed 2021-05-17 | ||||
| 2020-12-31 | 0.40% 10-K · filed 2022-03-31 | 0.38% 10-K · filed 2021-03-25 | |||
| 2020-03-31 | 1.67% 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | 2.00% 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |